Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 19/20 | 1.00 |
| ▸ | DPP8 | Q6V1X1 | 14/20 | 1.00 |
| ▸ | DPP7 | Q9UHL4 | 11/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1394444 | 1.00 | DPP4 (1.00) | DPP4DPP8DPP7 | |
| SCHEMBL21067640 | 1.00 | DPP4 (1.00) | DPP4DPP8DPP7 | |
| Hydrochloric Acid SCHEMBL5043367 | 0.99 | DPP4 (0.98) | DPP4DPP8DPP7 | |
| SCHEMBL27827304 | 0.85 | DPP4 (0.74) | DPP4DPP8DPP7 | |
| SCHEMBL388929 | 0.84 | DPP4 (1.00) | DPP4DPP8DPP7 | |
| SCHEMBL21067975 | 0.84 | DPP4 (1.00) | DPP4DPP8DPP7 | |
| SCHEMBL4708250 | 0.83 | DPP4 (1.00) | DPP4DPP8DPP7 | |
| SCHEMBL4761344 | 0.83 | DPP4 (1.00) | DPP4DPP8DPP7 | |
| SCHEMBL4761339 | 0.83 | DPP4 (1.00) | DPP4DPP8DPP7 | |
| Hydrochloric Acid SCHEMBL4160735 | 0.83 | DPP4 (0.98) | DPP4DPP8DPP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2322150-A2 | Method of identifying GLP-1 secretagogues | Arena Pharmaceuticals, Inc. (US) | 2011-05-18 | — | — | EP | disclosed |
| EP-2322152-A1 | Method of preparing a composition comprising a GPR119 agonist | Arena Pharmaceuticals, Inc. (US) | 2011-05-18 | — | — | EP | disclosed |
| EP-2322157-A1 | Composition for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood GLP-1 level | Arena Pharmaceuticals, Inc. (US) | 2011-05-18 | — | — | EP | disclosed |
| EP-2322156-A1 | Composition for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood GLP-1 level | Arena Pharmaceuticals, Inc. (US) | 2011-05-18 | — | — | EP | disclosed |
| EP-2253311-A2 | Use of GPR119 receptor agonists for increasing bone mass and for treating osteoporosis, as well as combination therapy relating thereto | Arena Pharmaceuticals, Inc. (US) | 2010-11-24 | — | — | EP | disclosed |
| EP-2116235-A1 | Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood GLP-1 level | Arena Pharmaceuticals, Inc. (US) | 2009-11-11 | — | — | EP | disclosed |
| EP-1808168-B1 | Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood GLP-1 level | ARENA PHARM INC (US) | 2009-06-03 | — | — | EP | disclosed |
| EP-1997484-A2 | Method of identifying GLP-1 secretagogues | Arena Pharmaceuticals, Inc. (US) | 2008-12-03 | — | — | EP | disclosed |
| EP-1808168-A1 | Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood GLP-1 level | Arena Pharmaceuticals, Inc. (US) | 2007-07-18 | — | — | EP | disclosed |